← Back to Analyst Consensus 
PCRX Buy
Pacira BioSciences, Inc.
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 1 upgrades / ▼ 4 downgrades / 2 reiterations from 6 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 9, 2026 | Truist Securities | downgrade | Buy → Hold | — | 54% |
| Oct 9, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| Oct 9, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Oct 8, 2026 | JP Morgan | upgrade | Underweight → Neutral | — | 54% |
| Oct 8, 2026 | Jefferies | downgrade | Buy → Hold | — | 52% |
| Oct 8, 2026 | Needham | downgrade | Buy → Hold | — | 50% |
| Oct 7, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Sep 23, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Sep 9, 2026 | Leerink Partners | initiate | — → Market Perform | — | 51% |
| Aug 5, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| Aug 5, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jul 1, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 1, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| May 1, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Mar 26, 2026 | Barclays | maintain | Equal-Weight → Equal-Weight | — | 53% |
| Jan 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $38 | 44% |
| Jan 9, 2026 | Needham | maintain | Buy → Buy | $30 | 50% |
| Dec 9, 2025 | Barclays | initiate | — → Equal-Weight | $27 | 53% |
| Nov 7, 2025 | Truist Securities | maintain | Buy → Buy | $28 | 54% |
| May 9, 2025 | Needham | maintain | Buy → Buy | $30 | 50% |
| Apr 8, 2025 | Needham | reiterate | Buy → Buy | $32 | 50% |
| Apr 8, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $65 | 44% |
| Feb 28, 2025 | Barclays | maintain | Overweight → Overweight | $24 | 53% |
| Feb 28, 2025 | Needham | maintain | Buy → Buy | $32 | 50% |
| Feb 28, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $70 | 44% |
| Jan 30, 2025 | Truist Securities | upgrade | Sell → Hold | $25 | 54% |
| Jan 14, 2025 | RBC Capital | reiterate | Sector Perform → Sector Perform | $18 | 55% |
| Jan 13, 2025 | Needham | maintain | Buy → Buy | $30 | 50% |
| Dec 17, 2024 | Needham | maintain | Buy → Buy | $30 | 50% |
| Dec 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $39 | 44% |
| Nov 12, 2024 | Barclays | maintain | Equal-Weight → Equal-Weight | $17 | 53% |
| Nov 8, 2024 | Needham | reiterate | Buy → Buy | $22 | 50% |
| Nov 7, 2024 | RBC Capital | maintain | Sector Perform → Sector Perform | $16 | 55% |
| Oct 4, 2024 | RBC Capital | maintain | Sector Perform → Sector Perform | $15 | 55% |
| Sep 24, 2024 | Jefferies | maintain | Buy → Buy | $18 | 52% |
| Aug 13, 2024 | Truist Securities | downgrade | Buy → Sell | $8 | 54% |
| Aug 12, 2024 | RBC Capital | downgrade | Outperform → Sector Perform | $14 | 55% |
| Aug 12, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $39 | 44% |
| Aug 12, 2024 | Needham | maintain | Buy → Buy | $22 | 50% |
| Aug 12, 2024 | JP Morgan | downgrade | Overweight → Underweight | $10 | 54% |
| Aug 1, 2024 | Jefferies | maintain | Buy → Buy | $30 | 52% |
| Jul 31, 2024 | Raymond James | maintain | Outperform → Outperform | $37 | 54% |
| Jul 31, 2024 | RBC Capital | maintain | Outperform → Outperform | $37 | 55% |
| Jul 31, 2024 | Needham | reiterate | Buy → Buy | $43 | 50% |
| Jul 25, 2024 | Truist Securities | maintain | Buy → Buy | $30 | 54% |
| Jul 3, 2024 | Piper Sandler | maintain | Overweight → Overweight | $42 | 54% |
| Jul 3, 2024 | Barclays | downgrade | Overweight → Equal-Weight | $25 | 53% |
| Jul 2, 2024 | Needham | reiterate | Buy → Buy | $43 | 50% |
| Jul 2, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $57 | 44% |
| May 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $57 | 44% |
Price Target Trend
May 5, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days